Driven by a mission to develop regenerative medicines for intractable diseases, BlueRock Therapeutics is advancing a novel Cell+Gene platform to develop, manufacture and deliver native cell and engineered cell therapies. By restoring lost function, these regenerative medicines have the potential to meaningfully alter the treatment paradigm for patients. BlueRock was founded in 2016 when Versant Ventures, a top-tier venture capital firm, and global pharmaceutical giant Bayer AG provided $225 million in one of the largest-ever Series A financings in biotech history. These investors backed BlueRock’s scientific founders and management with world-leading cell bioprocessing, translational, and manufacturing expertise. With access to numerous cell types that can restore function and express therapeutic payload, BlueRock’s platform has broad therapeutic application across many disease areas.